Drug safety watch for advanced thyroid cancer treatment
NCT ID NCT02185560
Summary
This study is monitoring the safety and long-term effectiveness of the drug sorafenib (NEXAVAR®) in patients with advanced thyroid cancer that cannot be removed by surgery. It will follow 453 patients in Japan for up to two years to track side effects and survival rates. The goal is to better understand how this already-approved drug performs in real-world use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Multiple Locations, Japan
Conditions
Explore the condition pages connected to this study.